Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma

Summary

The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo in subjects with locally advanced medullary thyroid cancer (MTC). The primary study objective is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group with the placebo treatment group in patients with advanced MTC.

Timeline

Start

2012-10

Primary completion

2013-04

Completion

2013-04

Outcome

Outcome not reported

Stopped (Enrollment): “Study was withdrawn due to unanticipated hassle in patient recruitment.”

Drugs

Indications